MDMA
- Half-Life (t½)
- PO: 8h
- Formula
- C11H15NO2
- Molecular Weight
- 193.25 g/mol
- Aliases
- 3,4-Methylenedioxymethamphetamine, Molly, Ecstasy
Pharmacological Mechanism
Reverses SERT, DAT, NET to cause non-exocytotic release of serotonin (principal), dopamine, noradrenaline. Also triggers oxytocin release. Subjective 'entactogenic' state (connection, empathy, emotional openness) distinct from classical psychedelics (5-HT2A agonism minor vs LSD/psilocybin). MAPS Phase 3 trials demonstrated strong PTSD efficacy; FDA rejected 2024 citing trial design concerns (second submission pending).
Half-Life & Elimination Curve (PO: 8h)
Plasma (PO)t½ Decay (8h)
- 0×t½0h100% (0.169 mg/L)
- 1×t½8h50% (84.3 µg/L)
- 2×t½16h25% (42.2 µg/L)
- 3×t½24h12.5% (21.1 µg/L)
- 4×t½32h6.3% (10.5 µg/L)
- 5×t½40h3.1% (5.27 µg/L)
Dosing Guidelines
- Oral (PO): Typical 120 mg
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 72% · Volume of Distribution (Vd): 420 L · Absorption (ka): 1.25 h⁻¹ (t½ka ≈ 33m) [PMID 10671903]
Pathways It Modulates
Target Organ Systems
Chemical Structure & Identifiers
- InChIKey: SHXWCVYOXRDMCX-UHFFFAOYSA-N
- SMILES: CC(CC1=CC2=C(C=C1)OCO2)NC
References